Pays: Canada
Langue: anglais
Source: Health Canada
MIDODRINE HYDROCHLORIDE
APOTEX INC
C01CA17
MIDODRINE
2.5MG
TABLET
MIDODRINE HYDROCHLORIDE 2.5MG
ORAL
100
Prescription
ALPHA-ADRENERGIC AGONISTS
Active ingredient group (AIG) number: 0123066001; AHFS:
APPROVED
2006-03-13
Page 1 of 23 PRODUCT MONOGRAPH Pr APO-MIDODRINE MIDODRINE HYDROCHLORIDE TABLETS USP 2.5 MG AND 5 MG VASOPRESSOR APOTEX INC. DATE OF PREPARATION 150 SIGNET DRIVE OCTOBER 16, 2018 TORONTO, ONTARIO M9L 1T9 CONTROL NO. 219481 Page 2 of 23 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 4 SUMMARY PRODUCT INFORMATION ............................................................................. 4 INDICATIONS AND CLINICAL USE ................................................................................... 4 CONTRAINDICATIONS ........................................................................................................ 5 WARNINGS AND PRECAUTIONS ....................................................................................... 5 ADVERSE REACTIONS ......................................................................................................... 7 DRUG INTERACTIONS ......................................................................................................... 9 DOSAGE AND ADMINISTRATION ................................................................................... 10 OVERDOSAGE ...................................................................................................................... 11 ACTION AND CLINICAL PHARMACOLOGY ................................................................. 11 STORAGE AND STABILITY ............................................................................................... 12 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 13 PART II: SCIENTIFIC INFORMATION ............................................................................. 14 PHARMACEUTICAL INFORMATION ............................................................................... 14 CLINICAL TRIALS ............................................................................................................... 16 DETAILED PHARMACOLOGY ........................................... Lire le document complet